ProGen Co., Ltd. is a biotechnology company, which engages in the research and development of antibody therapeutics. It offers Neo Tri-ImmunoGlobulin (NTIG), a platform technology optimized for the development of anti-cancer and immune disease treatments. The company was founded on October 21, 1998 and is headquartered in Seoul, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company